Behind pharmacologic β-blockade action is the ability of these molecules to inhibit the excessive catecholamine stimulation of inotropic βARs that induce myocyte cell death so resulting in cardiac deterioration, and changes in ventricular mass and that promote ventricular dilation through HF (Mann, 1999; Bristow, 2011). This evidence concerns the gene CTBP1 and hydrops fetalis.